Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Nov 22, 2023
Product Development
The next chapter in the XLMTM gene therapy story
New evidence reveals the gene therapy from Astellas that led to four patient deaths may also be very effective
BioCentury | Aug 8, 2023
Data Byte
How Astellas’ recent deals fit its focus areas
Japanese pharma has done a dozen therapeutics deals so far this year, with at least seven showcasing how it’s building within defined focus areas
BioCentury | Jun 8, 2023
Emerging Company Profile
KateTx: sending more AAV to muscle, less to liver
Kate’s platform for increasing the potency and decreasing the liver tox of AAVs has attracted Astellas as a partner
BioCentury | Feb 7, 2023
Management Tracks
Astellas shuffles top management amid push to reshape strategically
As pharma implements growth plan to look beyond Xtandi, rising CEO Okamura figures to execute on launches, develop in newer modalities
BioCentury | Oct 15, 2021
Product Development
Gene therapy’s translational problem
How regulators and companies are tackling the safety issues disrupting development
BioCentury | Oct 14, 2021
Product Development
A year of gene therapy setbacks
And how they’re shifting the development landscape
BioCentury | Sep 15, 2021
Product Development
What the latest patient death means for gene therapy development
Dosing, pre-existing liver pathology and vector-specific effects all possible contributors to fourth death in Astellas trial
BioCentury | Sep 2, 2021
Deals
Sept. 1 Quick Takes: New warnings for JAK inhibitors shave billions off AbbVie’s valuation
Plus: Asher’s $108M B round, Mesoblast denial, Astellas’ liver tox concerns and more
BioCentury | Dec 31, 2020
Regulation
Dec. 30 Quick Takes: A first for Chi-Med; plus Orphazyme, BMS, FDA REMS, Pfizer, Astellas, Alkermes, Osmotica, Quanterix, Ampio and Novartis
Chi-Med’s surufatinib approved in ChinaChina’s National Medical Products Administration (NMPA) approved an NDA from Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) for Sulanda
BioCentury | Jun 30, 2020
Product Development
Second death in Audentes gene therapy trial may highlight need for more careful dosing
Astellas gained AT132, Audentes’ lead program, via its $3B acquisition of the biotech last year
Items per page:
1 - 10 of 25